Hemostemix Investor Presentation 2022 - ACP-01 Stem Cell Treatment

Hemostemix presents its stem cell therapeutic platform, highlighting the ACP-01 treatment for ischemic cardiomyopathy and critical limb ischemia, based on 500 clinical treatments. The presentation outlines the company's research and development strategy, regulatory pathways, and commercialization potential for its novel stem cell therapies.